Regenacy Pharmaceuticals
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
303 Wyman St Ste 300, Waltham, Massachus...Phone Number
(617) 415-5030Website
www.regenacy.comRevenue
$5.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Regenacy Pharmaceuticals
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. The company were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinostat, a clinical stage, orally bioavailable, HDAC6 selective inhibitor, for a range of non-cancer disease indications. The company also have a unique and proprietary portfolio of selective HDAC1,2 inhibitors with potential for treating cancer, hemoglobinopathies, and cognitive dysfunction.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Regenacy Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Regenacy Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Regenacy Pharmaceuticals recently announced quarterly report
Regenacy Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Regenacy Pharmaceuticals launches new products
Click to see if Regenacy Pharmaceuticals had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Regenacy Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Regenacy Pharmaceuticals has new funding data
Congratulate Masked Content for being promoted to Masked Content at Regenacy Pharmaceuticals
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Regenacy Pharmaceuticals
Compare insights from companies similar to Regenacy Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Regenacy Pharmaceuticals
$5.2M
11-50
Private
$39.3M
2016
N/A
$7.7M
11-50
Public
$340.5M
2015
KB
Kristi BalacyHead Senior Director, Clinical Development Operations & of Clinical Operations
Company Profile Activity
Activity Insights
Regenacy Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Regenacy Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Regenacy Pharmaceuticals.
Regenacy Pharmaceuticals financials insights
Gather financial insights about Regenacy Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$30M
2022
Series B
$9.3M
Regenacy Pharmaceuticals Tech Stack
A closer look at the technologies used by Regenacy Pharmaceuticals
Most Recent Scoops
Funding
Promotion
Executive Move
Executive Moves
Funding
Funding
Funding
Regenacy Pharmaceuticals News & Media
Regenacy Pharmaceuticals Announces Completion of Enrollment for Phase 2 Study in Diabetic Peripheral Neuropathy & $9.3 Million Series B Financing
WALTHAM, Mass.--(BUSINESS WIRE)--Regenacy announces completion of enrollment of phase 2 study of ricolinostat in painful diabetic peripheral neuropathy and Series B financing.Regenacy Announces the Formation of a Joint Venture with 3E Bioventures to Develop Ricolinostat in China and the Start of a U.S. Phase 2 Study in Painful Diabetic Peripheral Neuropathy
WALTHAM, Mass.--(BUSINESS WIRE)--Regenacy announces formation of joint venture company Beijing 3E-Regenacy with 3E Bioventures and start of Phase 2 study of ricolinostat for DPNRegenacy Pharmaceuticals Appoints David Michelson, M.D., as Chief Medical Officer
WALTHAM, Mass.--(BUSINESS WIRE)--Regenacy announces the appointment of David Michelson, M.D., as Chief Medical OfficerRegenacy Pharmaceuticals Appoints David Michelson, MD, as Chief Medical Officer
Regenacy announces the appointment of David Michelson, M.D., as Chief Medical Officer
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Regenacy Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function. The company were founded in December 2016 following the acquisition of Acetylon Pharmaceuticals by Celgene. Regenacy received exclusive rights to ricolinost... Read More
